{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:06:53Z","timestamp":1765609613281,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.rpsm.2014.05.004","type":"journal-article","created":{"date-parts":[[2014,10,19]],"date-time":"2014-10-19T08:18:10Z","timestamp":1413706690000},"page":"166-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Estudio farmacogen\u00e9tico del tratamiento a largo plazo con antipsic\u00f3ticos de segunda generaci\u00f3n y sus efectos adversos metab\u00f3licos (Estudio SLiM): justificaci\u00f3n, objetivos, dise\u00f1o y descripci\u00f3n de la muestra"],"prefix":"10.1016","volume":"7","author":[{"given":"Laura","family":"Pina-Camacho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Covadonga M.","family":"D\u00edaz-Caneja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar A.","family":"Saiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Bobes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iluminada","family":"Corripio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Grasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Rodriguez-Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miryam","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Sanju\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelio","family":"Garc\u00eda-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Tapia-Casellas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"\u00c1lvarez-Bl\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fraguas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Mitjans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e1rbara","family":"Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celso","family":"Arango","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpsm.2014.05.004_bib0005","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/archgenpsychiatry.2012.647","article-title":"National trends in the office-based treatment of children, adolescents, and adults with antipsychotics","volume":"69","author":"Olfson","year":"2012","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1192\/bjp.bp.111.104257","article-title":"Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010","volume":"200","author":"Ilyas","year":"2012","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0015","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.euroneuro.2010.07.002","article-title":"Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons","volume":"21","author":"Fraguas","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0020","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"1\u20133","key":"10.1016\/j.rpsm.2014.05.004_bib0025","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.schres.2006.09.025","article-title":"Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study","volume":"90","author":"Bobes","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1888-9891(09)70714-1","article-title":"Enfermedad cardiovascular y diabetes en personas con enfermedad mental grave","volume":"2","author":"De Hert","year":"2009","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(02)00498-X","article-title":"Obesity as a risk factor for antipsychotic noncompliance","volume":"66","author":"Weiden","year":"2004","journal-title":"Schizophr Res"},{"issue":"2\u20133","key":"10.1016\/j.rpsm.2014.05.004_bib0040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.schres.2011.03.018","article-title":"Lack of physical activity during leisure time contributes to an impaired health related quality of life in patients with schizophrenia","volume":"129","author":"Vancampfort","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0045","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-244X-12-20","article-title":"A patient perspective of the impact of medication side effects on adherence: Results of a cross-sectional nationwide survey of patients with schizophrenia","volume":"12","author":"Dibonaventura","year":"2012","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0050","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1517\/14656560903508762","article-title":"Pharmacogenetic considerations in the treatment of psychiatric disorders","volume":"11","author":"Lohoff","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rpsm.2011.05.001","article-title":"Pharmacogenetics in psychiatry: The need to prove its benefits","volume":"4","author":"Arranz","year":"2011","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0060","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.2011.339","article-title":"Pharmacogenomic testing: Knowing more, doing better","volume":"91","author":"Lunshof","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.rpsm.2014.05.004_bib0065","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.metabol.2012.08.017","article-title":"Personalized medicine in psychiatry: New technologies and approaches","volume":"62","author":"Costa e Silva","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.tips.2010.11.008","article-title":"Pharmacogenomic biomarkers: New tools in current and future drug therapy","volume":"32","author":"Sim","year":"2011","journal-title":"Trends Pharmacol Sci"},{"year":"1994","series-title":"Diagnostic and statistical manual of mental disorders","key":"10.1016\/j.rpsm.2014.05.004_bib0075"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0080","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0085","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/archpedi.157.8.821","article-title":"Prevalence of a metabolic syndrome phenotype in adolescents: Findings from the third National Health and Nutrition Examination Survey, 1988-1994","volume":"157","author":"Cook","year":"2003","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0090","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.chi.0000220851.94392.30","article-title":"Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents","volume":"45","author":"Correll","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0095","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/01.crd.0000380842.14048.7e","article-title":"Diagnosis and management of the metabolic syndrome. An American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary","volume":"13","author":"Grundy","year":"2005","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0100","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2009.08.040","article-title":"Antipsychotic dose equivalents and dose-years: A standardized method for comparing exposure to different drugs","volume":"67","author":"Andreasen","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0105","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/01.jcp.0000096247.29231.3a","article-title":"Chlorpromazine equivalents versus defined daily doses: How to compare antipsychotic drug doses?","volume":"23","author":"Rijcken","year":"2003","journal-title":"J Clin Psychopharmacol"},{"year":"2004","series-title":"Curvas y tablas de crecimiento: estudios longitudinal y transversal","author":"Sobradillo","key":"10.1016\/j.rpsm.2014.05.004_bib0110"},{"issue":"2 Suppl 4th Report","key":"10.1016\/j.rpsm.2014.05.004_bib0115","first-page":"555","article-title":"The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents","volume":"114","year":"2004","journal-title":"Pediatrics"},{"year":"1976","series-title":"ECDEU Assessment Manual for Psychopharmacology.","author":"Guy","key":"10.1016\/j.rpsm.2014.05.004_bib0120"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1023\/A:1015081805439","article-title":"Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-lite) in a community sample","volume":"11","author":"Kolotkin","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The U.K.U. side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"1\u20132","key":"10.1016\/j.rpsm.2014.05.004_bib0135","first-page":"20","article-title":"Simultaneous determination of five antipsychotic drugs in rat plasma by high performance liquid chromatography with ultraviolet detection","volume":"856","author":"Zhang","year":"2007","journal-title":"J Chromatog B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/clpt.2011.97","article-title":"Mechanisms and genetics of antipsychotic-associated weight gain","volume":"90","author":"Balt","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0145","doi-asserted-by":"crossref","first-page":"405","DOI":"10.31887\/DCNS.2009.11.4\/tlencz","article-title":"Pharmacogenetics of antipsychotic-induced side effects","volume":"11","author":"Lencz","year":"2009","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0150","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/mp.2011.109","article-title":"Pharmacogenetics of antipsychotic-induced weight gain: Review and clinical implications","volume":"17","author":"Lett","year":"2012","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/ng.301","article-title":"Genome-wide association study for early-onset and morbid adult obesity identifies three new risk loci in European populations","volume":"41","author":"Meyre","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0160","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2217\/pgs.11.67","article-title":"Pharmacogenetic testing to predict antipsychotic-induced weight gain: A systematic review","volume":"12","author":"Risselada","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0165","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ng.686","article-title":"Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index","volume":"42","author":"Speliotes","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0170","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.274","article-title":"Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity","volume":"41","author":"Thorleifsson","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0175","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ng.287","article-title":"Six new loci associated with body mass index highlight a neuronal influence on body weight regulation","volume":"41","author":"Willer","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0180","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/sj.mp.4001981","article-title":"The risk for depression conferred by stressful life events is modified by variation at the serotonin transporter 5HTTLPR genotype: Evidence from the Spanish PREDICT-Gene cohort","volume":"12","author":"Cervilla","year":"2007","journal-title":"Mol Psychiatry"},{"year":"2009","series-title":"PASW Statistics for Windows","key":"10.1016\/j.rpsm.2014.05.004_bib0185"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0190","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/cap.2007.0138","article-title":"Antipsychotic treatment in child and adolescent first-episode psychosis: A longitudinal naturalistic approach","volume":"18","author":"Castro-Fornieles","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0195","first-page":"217","article-title":"Secondary effects of antipsychotic treatment in naive or quasi-naive children and adolescents: Design of a follow-up protocol and baseline results","volume":"5","author":"Merchan-Naranjo","year":"2012","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0200","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1034\/j.1600-0447.107.s416.4.x","article-title":"The European Schizophrenia Outpatient Health Outcomes Study: Baseline findings across country and treatment","author":"Haro","year":"2003","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0205","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s00787-009-0749-5","article-title":"Olanzapine compared to quetiapine in adolescents with a first psychotic episode","volume":"18","author":"Arango","year":"2009","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0210","first-page":"1","article-title":"Polypharmacy with antidepressants in children and adolescents","author":"Diaz-Caneja","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0215","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaac.2010.07.007","article-title":"National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007","volume":"49","author":"Comer","year":"2010","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.rpsm.2014.05.004_bib0220","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4088\/JCP.v69n0210","article-title":"Comparing the use and discontinuation of antipsychotics in clinical practice: An observational study","volume":"69","author":"Taylor","year":"2008","journal-title":"J Clin Psychiatry"},{"year":"2002","series-title":"Research methods in Psychology","author":"Heiman","key":"10.1016\/j.rpsm.2014.05.004_bib0225"}],"container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989114000950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989114000950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:29:48Z","timestamp":1761823788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1888989114000950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1888989114000950"],"URL":"https:\/\/doi.org\/10.1016\/j.rpsm.2014.05.004","relation":{},"ISSN":["1888-9891"],"issn-type":[{"type":"print","value":"1888-9891"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estudio farmacogen\u00e9tico del tratamiento a largo plazo con antipsic\u00f3ticos de segunda generaci\u00f3n y sus efectos adversos metab\u00f3licos (Estudio SLiM): justificaci\u00f3n, objetivos, dise\u00f1o y descripci\u00f3n de la muestra","name":"articletitle","label":"Article Title"},{"value":"Revista de Psiquiatr\u00eda  y Salud Mental","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpsm.2014.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 SEP y SEPB. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}